Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 21 2024
0mins
Should l Buy DOCS?
Source: NASDAQ.COM
Overview of Janus Henderson Small Cap Growth Alpha ETF (JSML): Launched in 2016, JSML is a passively managed ETF focusing on small-cap growth stocks with assets over $242 million. It has an expense ratio of 0.30% and a current return of approximately 12.93% for the year.
Investment Considerations: While small-cap growth stocks offer high potential returns, they also come with higher risks. Investors should consider the ETF's holdings, sector allocations, and compare it with similar ETFs like iShares Russell 2000 Growth ETF and Vanguard Small-Cap Growth ETF for better investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DOCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DOCS
Wall Street analysts forecast DOCS stock price to rise
18 Analyst Rating
14 Buy
4 Hold
0 Sell
Strong Buy
Current: 25.690
Low
25.00
Averages
42.75
High
63.00
Current: 25.690
Low
25.00
Averages
42.75
High
63.00
About DOCS
Doximity, Inc. provides a digital platform for the United States medical professionals. It offers marketing, hiring, and workflow solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare companies. Its marketing solutions enable its pharmaceutical and health system customers to get the right content, services, and peer connections to the right medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms, enabling them to identify, connect with, and hire from its network of both active and passive medical professional candidates, who might otherwise be missed through traditional recruiting channels. Its workflow solutions include its telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and connect with patients and colleagues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DoorDash's Revenue Miss Doesn't Detract from Strong Growth Story
- Significant Revenue Growth: DoorDash's Q1 revenue increased by 33% year-over-year to $4.04 billion, largely driven by the acquisition of Deliveroo, showcasing the company's strong performance in market expansion.
- Order Volume Surge: Total orders rose by 27% to 933 million, with marketplace gross order value jumping 37% to $31.6 billion, indicating that the company is not only adding orders but also capturing larger ones, particularly in the fast-growing grocery and retail categories.
- Profit Pressure Intensifies: Despite revenue growth, diluted EPS fell from $0.44 to $0.42, primarily due to integration costs from Deliveroo and ongoing investments in autonomous delivery, highlighting the profit pressures faced during expansion.
- Optimistic Future Outlook: Management maintained its full-year outlook, expecting modest margin gains, although heavy investment will continue, indicating the company's need to prove that these investments can translate into operational leverage.
See More
Investment Outlook for Doximity Stock
- Strong Market Position: Doximity (DOCS) operates as a leading digital healthcare network with over 80% of U.S. physicians registered, creating a powerful network effect that makes it difficult for competitors to replicate, thus continuing to attract advertising spend from pharmaceutical companies and healthcare institutions.
- Robust Financial Performance: With approximately 95% of its revenue derived from subscription-based, multi-year contracts, DOCS has seen its net margins rise from 25% to nearly 39%, reflecting high capital efficiency and stable cash flow generation capabilities.
- Significant Growth Potential: The company is expected to maintain low double-digit growth driven by expansion into nurse practitioners, international markets, and deeper hospital system penetration, although it faces risks from regulatory changes and AI-driven disruptions.
- Declining Investor Interest: The number of hedge funds holding DOCS increased from 44 to 51 by Q4 2024, yet market confidence in its future performance has weakened, leading to a stock price decline of approximately 44.29% since previous coverage due to slowing growth expectations.
See More
DOXIMITY INC: TRUIST SECURITIES LOWERS RATING TO HOLD FROM BUY; REDUCES TARGET PRICE TO $29 FROM $37
Company Overview: Doximity, a healthcare technology company, has made significant changes to its financial outlook.
Target Price Adjustment: The company has cut its target price from $37 to $29, reflecting a more conservative market expectation.
See More
Doximity CFO Anna Bryson Resigns Amid Transition
- Executive Departure: Doximity accepted the resignation of CFO Anna Bryson on April 13, 2026, following her medical leave, indicating potential challenges in executive stability that may affect investor confidence.
- Interim Financial Leadership: Since February 3, 2026, Chief Accounting Officer Siddharth Sitaram has been serving as the interim principal financial and accounting officer until a new CFO is appointed, which could lead to delays in financial decision-making and impact strategic execution.
- Guidance Reaffirmation: Doximity reaffirmed its previously issued guidance for Q4 and the full fiscal year ending March 31, 2026, demonstrating the company's intent to maintain stable financial expectations amid uncertain market conditions, aiming to bolster investor confidence.
- Uncertain Growth Outlook: Despite the reaffirmation of guidance, the market outlook for Doximity remains murky, which could affect its stock performance, prompting investors to closely monitor the upcoming CFO appointment and its implications for the company's strategy.
See More
Market Volatility Following Anthropic's Managed Agents Announcement
- AI Disruption: Anthropic's announcement of Managed Agents has sparked investor concerns about potential disruptions to existing SaaS business models, leading to notable declines in stocks such as Doximity, Guidewire, and Intuit, which fell by 3%, 5%, and 5%, respectively.
- Overreaction in Market: Despite the severe market reaction to AI agents, analysts suggest that significant price drops may present buying opportunities for high-quality stocks, particularly as investors look for long-term value amidst volatility.
- Health Catalyst Volatility: Health Catalyst has experienced 51 moves greater than 5% over the past year, with its current share price at $1.03, representing a 77.3% decline from its 52-week high of $4.52, indicating cautious market sentiment regarding its future prospects.
- Geopolitical Tensions: Recent geopolitical tensions have escalated, pushing oil prices to new highs, which could increase business costs and trigger inflation, further impacting global economic growth, necessitating investor vigilance on related developments.
See More
Doximity Reports Weak Earnings, Stock Down 31.2%
- Earnings Beat: Doximity reported revenues of $185.1 million, a 9.8% year-over-year increase, exceeding analyst expectations by 2%, yet the revenue and EBITDA guidance for the next quarter fell short, leading to negative market sentiment.
- Significant Stock Decline: Following the earnings report, Doximity's stock plummeted by 31.2%, currently trading at $22.93, indicating investor concerns regarding future growth prospects.
- Industry Performance Comparison: Within the vertical software sector, Doximity's performance was notably weak, as the overall industry reported a 2.5% revenue beat in Q4, highlighting Doximity's struggle to keep pace with sector growth.
- Shifting Market Sentiment: Amid rising geopolitical risks, investor confidence in the software sector has waned, and Doximity's earnings report failed to alleviate concerns about its future profitability.
See More
DoorDash's Revenue Miss Doesn't Detract from Strong Growth Story
- Significant Revenue Growth: DoorDash's Q1 revenue increased by 33% year-over-year to $4.04 billion, largely driven by the acquisition of Deliveroo, showcasing the company's strong performance in market expansion.
- Order Volume Surge: Total orders rose by 27% to 933 million, with marketplace gross order value jumping 37% to $31.6 billion, indicating that the company is not only adding orders but also capturing larger ones, particularly in the fast-growing grocery and retail categories.
- Profit Pressure Intensifies: Despite revenue growth, diluted EPS fell from $0.44 to $0.42, primarily due to integration costs from Deliveroo and ongoing investments in autonomous delivery, highlighting the profit pressures faced during expansion.
- Optimistic Future Outlook: Management maintained its full-year outlook, expecting modest margin gains, although heavy investment will continue, indicating the company's need to prove that these investments can translate into operational leverage.
See More
Investment Outlook for Doximity Stock
- Strong Market Position: Doximity (DOCS) operates as a leading digital healthcare network with over 80% of U.S. physicians registered, creating a powerful network effect that makes it difficult for competitors to replicate, thus continuing to attract advertising spend from pharmaceutical companies and healthcare institutions.
- Robust Financial Performance: With approximately 95% of its revenue derived from subscription-based, multi-year contracts, DOCS has seen its net margins rise from 25% to nearly 39%, reflecting high capital efficiency and stable cash flow generation capabilities.
- Significant Growth Potential: The company is expected to maintain low double-digit growth driven by expansion into nurse practitioners, international markets, and deeper hospital system penetration, although it faces risks from regulatory changes and AI-driven disruptions.
- Declining Investor Interest: The number of hedge funds holding DOCS increased from 44 to 51 by Q4 2024, yet market confidence in its future performance has weakened, leading to a stock price decline of approximately 44.29% since previous coverage due to slowing growth expectations.
See More
DOXIMITY INC: TRUIST SECURITIES LOWERS RATING TO HOLD FROM BUY; REDUCES TARGET PRICE TO $29 FROM $37
Company Overview: Doximity, a healthcare technology company, has made significant changes to its financial outlook.
Target Price Adjustment: The company has cut its target price from $37 to $29, reflecting a more conservative market expectation.
See More
Doximity CFO Anna Bryson Resigns Amid Transition
- Executive Departure: Doximity accepted the resignation of CFO Anna Bryson on April 13, 2026, following her medical leave, indicating potential challenges in executive stability that may affect investor confidence.
- Interim Financial Leadership: Since February 3, 2026, Chief Accounting Officer Siddharth Sitaram has been serving as the interim principal financial and accounting officer until a new CFO is appointed, which could lead to delays in financial decision-making and impact strategic execution.
- Guidance Reaffirmation: Doximity reaffirmed its previously issued guidance for Q4 and the full fiscal year ending March 31, 2026, demonstrating the company's intent to maintain stable financial expectations amid uncertain market conditions, aiming to bolster investor confidence.
- Uncertain Growth Outlook: Despite the reaffirmation of guidance, the market outlook for Doximity remains murky, which could affect its stock performance, prompting investors to closely monitor the upcoming CFO appointment and its implications for the company's strategy.
See More
Market Volatility Following Anthropic's Managed Agents Announcement
- AI Disruption: Anthropic's announcement of Managed Agents has sparked investor concerns about potential disruptions to existing SaaS business models, leading to notable declines in stocks such as Doximity, Guidewire, and Intuit, which fell by 3%, 5%, and 5%, respectively.
- Overreaction in Market: Despite the severe market reaction to AI agents, analysts suggest that significant price drops may present buying opportunities for high-quality stocks, particularly as investors look for long-term value amidst volatility.
- Health Catalyst Volatility: Health Catalyst has experienced 51 moves greater than 5% over the past year, with its current share price at $1.03, representing a 77.3% decline from its 52-week high of $4.52, indicating cautious market sentiment regarding its future prospects.
- Geopolitical Tensions: Recent geopolitical tensions have escalated, pushing oil prices to new highs, which could increase business costs and trigger inflation, further impacting global economic growth, necessitating investor vigilance on related developments.
See More
Doximity Reports Weak Earnings, Stock Down 31.2%
- Earnings Beat: Doximity reported revenues of $185.1 million, a 9.8% year-over-year increase, exceeding analyst expectations by 2%, yet the revenue and EBITDA guidance for the next quarter fell short, leading to negative market sentiment.
- Significant Stock Decline: Following the earnings report, Doximity's stock plummeted by 31.2%, currently trading at $22.93, indicating investor concerns regarding future growth prospects.
- Industry Performance Comparison: Within the vertical software sector, Doximity's performance was notably weak, as the overall industry reported a 2.5% revenue beat in Q4, highlighting Doximity's struggle to keep pace with sector growth.
- Shifting Market Sentiment: Amid rising geopolitical risks, investor confidence in the software sector has waned, and Doximity's earnings report failed to alleviate concerns about its future profitability.
See More
